User:SmilauerovaKristyna/sandbox2

PD-1 inhibitors
Initial clinical trial results with IgG4 PD1 antibody Nivolumab were published in 2010. It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first line setting, but is FDA approved in subsequent lines of therapy.

Pembrolizumab is another PD1 inhibitor that was approved by the FDA in 2014. Keytruda (Pembrolizumab) is approved to treat melanoma and lung cancer. It was shown, that patients with higher non-synonymous mutation burden in their tumours respond better to the treatment. Both their ORR (objective response rate) and PFS (progression-free survival) was shown to be higher than in patients with low non-synonymous mutation burden. This suggests, that tobacco smoking, due to its high carcinogenity, not only causes promotion of cancer, but also partially increases chances of the immune system to recognize and attack to the tumour.

Antibody BGB-A317 is a PD-1 inhibitor (designed to not bind Fc gamma receptor I) in early clinical trials.